Tandem Anellovirus Constructs for Scalable Vector Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing viral vectors for therapeutic delivery, such as in vitro circularization (IVC), are undesirable for large-scale processes and there is a need for new methods to produce genetic elements for enclosure in a proteinaceous exterior.
Innovation Solution
The development of nucleic acid constructs, specifically tandem constructs, that comprise a first and second copy of a genetic element sequence arranged in tandem, which can replicate using rolling circle replication and are used to produce anellovectors capable of delivering genetic material or therapeutic agents into eukaryotic cells by encapsulating them in a proteinaceous exterior.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If in vitro circularization (IVC) is used to produce viral vectors, then genetic elements can be enclosed in a proteinaceous exterior, but the method is undesirable for large-scale processes
Solution Approach 1:
The patent divides the genetic element production into two separate components: a first copy containing the therapeutic payload and a second copy containing replication facilitation sequences. This segmentation allows the second copy to be optimized specifically for high-level replication and production, while the first copy carries the therapeutic function. The separated architecture enables scalable production by allowing the replication sequences to drive high-level expression of the genetic element without requiring complex in vitro circularization procedures.
2Productivity
If higher levels of genetic element production are achieved, then delivery efficiency improves, but immune response may increase
Solution Approach 1:
The patent extracts the replication-facilitating sequences (uRFS and dRFS) from the therapeutic genetic element itself and places them in a separate second copy. This extraction allows the genetic element to achieve high production levels through robust replication sequences while the actual therapeutic payload remains distinct. The separation enables optimization of production without necessarily increasing the immunogenicity of the therapeutic payload, as the replication sequences can be designed to minimize immune recognition while maintaining high replication efficiency.
3Productivity
If tandem constructs with two copies of genetic element sequence are used, then replication efficiency improves, but construct complexity increases
Solution Approach 1:
The second copy in the tandem construct serves multiple functions: it contains the upstream replication-facilitating sequence (uRFS) and downstream replication-facilitating sequence (dRFS) that drive rolling circle replication, and it also provides structural framework for the complete genetic element. This multi-functionality allows a single second copy to perform both replication facilitation and structural roles, reducing the need for additional separate elements and simplifying the overall production system despite the tandem architecture.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The tandem constructs enable efficient production and delivery of genetic elements, achieving higher levels of genetic material encapsulation and minimizing immune response, with the anellovectors being capable of delivering therapeutic agents effectively while maintaining low integration frequency into the host genome.
Implementation Method 1
Without being bound by theory, a tandem construct described herein may replicate by rolling circle replication
Implementation Method 2
an anellovector (e.g., produced using a tandem construct as described herein) generally comprises a genetic element (e.g., a genetic element comprising or encoding an effector, e.g., an exogenous or endogenous effector, e.g., a therapeutic effector) encapsulated in a proteinaceous exterior
Data Source
AI summary
This invention relates generally to compositions for making anellovectors and uses thereof. For instance, a method herein can comprise providing a nucleic acid construct that comprises a first Anellovirus genome encoding an exogenous effector and a second Anellovirus genome or fragment thereof, arranged in tandem. In some embodiments, the nucleic acid construct results in production of an anellovector comprising an Anellovirus genetic element encoding the exogenous effector, enclosed in a proteinaceous exterior.